Cardiogen
Aliases: Ala-Glu-Asp-Arg · AEDR
Last verified: 2026-09-23
The short version
A cardiomyocyte-series tetrapeptide — heart-muscle support, anti-fibrosis; gerontological use. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical cardioprotection data. Status: research chemical. Not approved in the West.
Identity & type
- Molecular type
- bioregulator
- Origin
- A cardiomyocyte-series tetrapeptide — heart-muscle support, anti-fibrosis; gerontological use.
Mechanism of action
Regulation of cardiac-cell proliferation/differentiation; anti-apoptotic.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Cardiogen. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
1–5 mg/day SC in courses. A cardiac bioregulator: Russian experience in the elderly — better exertion tolerance; objective data limited.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A cardiac bioregulator: Russian experience in the elderly — better exertion tolerance; objective data limited.
Protocol — official vs community
Official / label
No approved protocol exists. Cardiogen is a research peptide bioregulator (Ala-Glu-Asp-Arg) with no registered drug product in any major market.
Duration: —
Preclinical cardioprotection data only; the anti-fibrosis and cardiomyocyte claims come from one author group.
Community (anecdotal)
1–5 mg SC daily for 10–20 days.
- Cycle:
- 1–2 courses per year.
- Break:
- Months between courses.
The regimen is the shared Khavinson course pattern; only the heart/cardioprotection targeting claim distinguishes it from the rest of the series.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical cardioprotection data.
Preclinical evidence
Preclinical cardioprotection data.
Known risks
- None reported.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.